Phase 3 study of Ketotransdel for pain - MPR
Links shared publicly online about this topic.
- 900total visits
Phase 3 study of Ketotransdel for pain - MPR
empr.com —
View full resource at empr.com
Tags: Pain, Dairy, Phase 3 Clinical Trial, News
Most Recently Shared on September 3, 2010 at 3:21 pm By:
MPR News: Phase 3 study of Ketotransdel for pain: Transdel announced positive results from its Phase 3 trial of Ke... http://bit.ly/b9Hzbk
Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain
news-medical.net — “BioLineRx announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.” View full resource at news-medical.net
Most Recently Shared on December 6, 2011 at 2:58 pm By:
News-Medical.Net Oncology and Health News
Oncology News: Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain: BioLineRx anno... http://t.co/vZ3buKTZ
Butrans (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management - Drugs.com MedNews
drugs.com — “A pivotal Phase 3 study of Butrans (buprenorphine) Transdermal System CIII in opioid-naive patients with moderate-to-severe chronic low back pain demonstrated s” View full resource at drugs.com
Most Recently Shared on October 26, 2011 at 6:02 pm By:
Drugs and Devices OW OW Health
Butrans (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and ... http://t.co/yjmTMQRA #drug
PROLENSA eye drops for cataract surgery patients
eyedocnews.com — “ISTA reports results of studies” View full resource at eyedocnews.com
Most Recently Shared on October 18, 2011 at 11:46 am By:
Dr. Ari Weitzner Doctor, Ophthalmologist, and Physician
Discuss: ISTA Pharmaceuticals Announces Phase 3 Results for PROLENSA(TM) Eye Drops for Treatment of Pain and Inf... http://t.co/jBS48JJZ
Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain (Nasdaq:ZGNX)
globenewswire.com — “Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it will host a conference call at 8:30 a.m. ET on Wednesday, August 17, 2011, to discuss the top-line results from its pivotal Phase 3 efficacy study (801) of Zohydro(tm) (hydrocodone bitartrate) extended-release capsules. Zohydro is being evaluated for the treatment of moderate to severe chronic pain in patients requir” View full resource at globenewswire.com
Most Recently Shared on August 17, 2011 at 7:42 pm By:
Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain: SA... http://t.co/8PFYiuI
Multiple Migraine Attacks - Promising Results For SUMAVEL DosePro Phase 4 Clinical Trial
medicalnewstoday.com — “The publication of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery system Phase 4 clinical study results were announced by Zogenix, Inc., a pharmaceutical company commercializing and” View full resource at medicalnewstoday.com
Most Recently Shared on August 6, 2011 at 4:05 pm By:
Multiple Migraine Attacks - Promising Results For SUMAVEL DosePro Phase 4 Clinical Trial http://mnt.to/3YNJ #healthnews
Phase 3 Safety Study of MoxDuo IR for Postoperative Pain - ONA
oncologynurseadvisor.com — “QRxPharma Limited announced additional data from its Phase 3 safety study of MoxDuo IR for the treatment of patients experiencing moderate to severe postoperative pain following bunionectomy surgery.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 29, 2011 at 2:07 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 Safety Study of MoxDuo IR for Postoperative Pain http://goo.gl/fb/7P2OC
Pfizer's Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury
medicalnewstoday.com — “Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoi” View full resource at medicalnewstoday.com
Most Recently Shared on June 22, 2011 at 5:05 pm By:
MNT Pain News Health News and Pain Management
Pfizer's Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord In... http://mnt.to/3Xxq
Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint
news-medical.net — “Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.” View full resource at news-medical.net
Most Recently Shared on June 22, 2011 at 5:48 am By:
Epilepsy News: Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint: Pfizer Inc. annou... http://bit.ly/irWH6C
Data From Phase 1 Study Of NKTR-181 Demonstrate Proof-of-Concept For Nektar's Novel Opioid Analgesic Candidate
medicalnewstoday.com — “Nektar Therapeutics (NASDAQ: NKTR) announced positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate. Interi” View full resource at medicalnewstoday.com
Most Recently Shared on June 8, 2011 at 7:05 am By:
MNT Pain News Health News and Pain Management
Data From Phase 1 Study Of NKTR-181 Demonstrate Proof-of-Concept For Nektar's Novel Opioid Analgesic Candidate http://mnt.to/3WTm #pain
Fentanyl Sublingual Spray Significantly More Effective Than Placebo at Relieving Breakthrough Cancer Pain - ONA
oncologynurseadvisor.com — “Fentanyl sublingual spray was significantly more effective at relieving breakthrough cancer pain at 30 minutes compared with placebo. That’s the conclusion of a randomized, double-blind, placebo-controlled, Phase 3 study that was presented during the American Pain Society’s 30th Annual Scientific Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 21, 2011 at 1:06 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Fentanyl Sublingual Spray Significantly More Effective Than Placebo at Relieving Breakthrough… http://goo.gl/fb/7y8Ub
Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients - Drugs.com MedNews
drugs.com — “Progenics Pharmaceuticals, Inc. (Nasdaq PGNX) today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year phase 3 safety study of” View full resource at drugs.com
Most Recently Shared on May 20, 2011 at 2:07 pm By:
Drugs and Devices OW OW Health
Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patien... http://bit.ly/l5oybs #drug
Salix Pharmaceuticals Reviews Data Presentations at American Pain Society Annual Meeting - Drugs.com MedNews
drugs.com — “May 20, 2011 - Salix Pharmaceuticals, Ltd. (NASDAQ SLXP) today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone” View full resource at drugs.com
Most Recently Shared on May 20, 2011 at 1:03 pm By:
Drugs and Devices OW OW Health
Salix Pharmaceuticals Reviews Data Presentations at American Pain Society Annual Meeting: RALEIGH, N.C.--(... http://bit.ly/mEj1mE #drug
Alkermes Presents Phase 2 Data Of ALKS 37 In Late-Breaking Oral Session At Digestive Disease Week Meeting
medicalnewstoday.com — “Alkermes, Inc. (NASDAQ: ALKS) today presented positive results from the phase 2 study of ALKS 37 for the treatment of opioid-induced constipation (OIC) in a late-breaking oral session at Digestive” View full resource at medicalnewstoday.com
Most Recently Shared on May 10, 2011 at 2:05 pm By:
MNT Pain News Health News and Pain Management
Alkermes Presents Phase 2 Data Of ALKS 37 In Late-Breaking Oral Session At Digestive Disease Week Meeting http://mnt.to/3VF4 #pain
Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, For Treatment Of Pain
medicalnewstoday.com — “Nektar Therapeutics (Nasdaq: NKTR) announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKT” View full resource at medicalnewstoday.com
Most Recently Shared on March 22, 2011 at 9:05 am By:
MNT Pain News Health News and Pain Management
Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, For Treatment Of Pain http://mnt.to/3Sxw #pain
BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain
news-medical.net — “BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.” View full resource at news-medical.net
Most Recently Shared on February 18, 2011 at 10:09 am By:
News-Medical.Net Oncology and Health News
Oncology News: BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain: BioDelivery... http://bit.ly/g97o9Q
Advertisement
